Herbert Von Der Eltz

This inventor holds 67 USPTO granted patents and 6 published patent applications, plus 10 CIPO patents and 12 EPO patents, primarily in Nucleic Acid Technologies (CPC class 536 ). Top assignees: Boehringer Mannheim Gmbh, Roche Diagnostics Operations, Inc., Roche Molecular Systems, Inc.. Active years: 1986-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Herbert Von Der Eltz. Retrieved from https://idiyas.com/inventor/herbert-von-der-eltz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 67 (Patent Applications = 6)

% Patents Active = 77.6

CIPO Patents = 10

EPO Patents = 12 (Patent Applications = 7)

Average Co-Inventor Count = 3.9

ph-index = 11

Forward Citations = 1,315(Granted Patents)

Forward Citations (Not Self Cited) = 1,282(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Woilheim, DE (1995)
Weiheim, DE (2004)
Weilhelm, DE (2010)
Wielheim, DE (2020)
Weilheim, DE (1986 - 2022)

Company Filing History:

23 out of 1,164

Boehringer Mannheim Gmbh

patents

23 out of 1,700

Roche Diagnostics Operations, Inc.

patents

12 out of 647

Roche Molecular Systems, Inc.

patents

4. 8 out of 489

Roche Diagnostics Gmbh

patents

5. 3 out of 533

University of Toronto

patents

where one patent can have more than one assignee

Years Active: 1986-2022

Loading Chart...

Areas of Expertise:

Oligonucleotide Probes

Heart Failure Assessment

Nucleic Acid Detection

Immunoassay

Bacterial Cell Lysis

Vitamin D Measurement

Protease Inhibitors

Heterocyclic Compounds

Nucleic Acid Amplification

Microparticle Production

Fluorescence Polarization

Nucleotide Analogs

67 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11421266 - Set of oligonucleotide probes as well as methods and uses thereto (2022-08-23),

2. 10996229 - Use of IGFBP-7 in the assessment of heart failure (2021-05-04),

3. 10640815 - Set of oligonucleotide probes as well as methods and uses thereto (2020-05-05),

4. 10633460 - Binding agent (2020-04-28),

5. 10488422 - Use of IGFBP-7 in the assessment of heart failure (2019-11-26),

6. 9371509 - Reagents for lysis of bacterial cells (2016-06-21),

7. 9347091 - Set of oligonucleotide probes as well as methods and uses thereto (2016-05-24),

8. 9267954 - Use of SLIM-1 in the assessment of heart failure (2016-02-23),

9. 8445206 - Set of oligonucleotide probes as well as methods and uses thereto (2013-05-21),

10. 8101744 - Isolation and purification of nucleic acids with a solid phase (2012-01-24),

11. 8057997 - Nucleic acid binding compounds containing pyrazolo[3,4-D]pyrimidine analogues of purin-2,6-diamine and their uses (2011-11-15),

12. 8013147 - Heterocyclic compounds and their use in the detection of nucleic acids (2011-09-06),

13. 8003400 - Measurement of vitamin D (2011-08-23),

14. 7951598 - Differential hemolysis of a whole blood sample (2011-05-31),

15. 7906629 - Protease inhibitor conjugates and antibodies useful in immunoassay (2011-03-15),

Title: Herbert von der Eltz: Innovator in Genomic Probes and Heart Failure Assessment

Introduction

Herbert von der Eltz is a distinguished inventor based in Weilheim, Germany, known for his significant contributions to the field of biotechnology. With an impressive portfolio of 61 patents, he has made strides in innovations related to oligonucleotide probes and methods for assessing heart failure through novel biomarkers.

Latest Patents

Among his latest patents, Herbert has developed a set of single-stranded oligonucleotide probes, which are designed to target specific genomic sequences. This patent not only illustrates his expertise in genomic research but also encompasses a method for detecting relevant genomic target sequences using these probes. Additionally, he has introduced a kit that includes these probes alongside other essential components for effective analysis.

Another pivotal patent addresses the use of IGFBP-7, a marker for heart failure assessment. This invention outlines a method involving the measurement of IGFBP-7 concentrations within samples, potentially combined with other heart failure markers, to evaluate the severity of the condition. The method represents a valuable advancement in clinical diagnostics, enabling better patient outcomes through early detection.

Career Highlights

Herbert's professional journey includes impactful roles at reputable companies such as Boehringer Mannheim GmbH and Roche Diagnostics Operations, Inc. His work at these organizations has significantly contributed to advancements in medical diagnostics and therapeutic innovations, showcasing his commitment to enhancing healthcare.

Collaborations

Throughout his career, Herbert has collaborated with notable colleagues, including Frank Bergmann and Frank Seela. These partnerships have fostered an environment of creativity and innovation, resulting in groundbreaking solutions in the medical field.

Conclusion

Herbert von der Eltz stands out as a leading inventor whose work in the development of oligonucleotide probes and heart failure assessment methods highlights the importance of innovation in biotechnology. His patents not only advance scientific understanding but also pave the way for improved diagnostic tools, ultimately benefiting patient care in the healthcare industry.

Profile summary based on public USPTO records.